Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Unger Takes Over ODE I As Acting Director; Temple To Focus On Clinical Science Role

Jan 30 2012

• By Derrick Gingery

Related Content

FDA’s Temple Sees Sentinel As Important Tool For Confirming And Analyzing Drug Adverse Events

Jan 23 2012

Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says

Nov 14 2011

<i>Pradaxa</i> Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices

Apr 01 2011

FDA's Marciniak vs. Unger: Cardio Experts Divided On GSK's RECORD Study

Jul 19 2010

FDA, EMA Decisions On Avandia Reflect The Power Of REMS

Sep 27 2010

Related Companies

Boehringer Ingelheim GmbH

GSK plc

Additional Topics

United States Regulation BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window